3rd Quarter - Termination

MYRIAD GENETIC LABORATORIES, INC. for MYRIAD GENETIC LABORATORIES, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$180,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Aug 31, 2018

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Termination (this page) Sep 4, 2018 $180,000 Replaced
3rd Quarter - Termination Amendment Oct 16, 2018 $160,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113- 93) - payment and coding for laboratory tests

LobbyistCovered position, as disclosed
KIMBERLY LINTHICUM Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Regulation of laboratory developed tests - discussion draft (no HR #) Diagnostic Accuracy and Innovation Act (DAIA)

LobbyistCovered position, as disclosed
KIMBERLY LINTHICUM Leg Director, Rep Bob Franks (1997-2000) Leg Correspondent, Rep Charles Taylor (1997) Leg Correspondent, Rep Bill Martini (1995-1996)

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.